You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Details for Patent: 9,732,092


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,732,092
Title:Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Abstract:Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s):Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun, Elizabeth M. Bacon, Philip Anthony Morganelli, Mingzhe Ji
Assignee:Gilead Sciences Inc
Application Number:US15/349,934
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Comprehensive Analysis of U.S. Patent 9,732,092: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 9,732,092, granted on August 15, 2017, pertains to a novel pharmaceutical invention, primarily focusing on specific compounds, formulations, or methods associated with a therapeutic area. Its claims delineate the boundaries of the invention, influencing its patentability, enforceability, and competitive landscape. This review provides a detailed examination of the patent's scope, claims, and position within the broader patent landscape, synthesizing legal, technical, and strategic insights to aid decision-makers in pharmaceutical R&D, licensing, and IP management.


What Is the Scope of U.S. Patent 9,732,092?

Patent Abstract and Technical Summary

The patent claims priority to an earlier application and is directed towards a specific class of chemical compounds, methods of synthesis, pharmaceutical compositions, and therapeutic applications. Its core innovation involves:

  • The structural features of certain compounds with specified substituents
  • Methods for their preparation
  • Use of these compounds for treating specific diseases or conditions, such as cancers, inflammatory disorders, or neurological conditions

Note: Exact chemical structures and therapeutic targets are described in the specification, typically including detailed formulations and experimental data demonstrating efficacy.

Scope Determination Through Claim Language

The scope hinges on the language used in the independent claims, which generally define the essential elements of the invention. For instance, the key claims may:

  • Cover a chemical compound characterized by a core structure with defined substituents
  • Encompass pharmaceutical compositions containing the compound
  • Encompass methods of treating particular diseases with the compound

Example Claim Structure:

Element Description
Compound A chemical formula representing the core structure with optional substitutions
Method Administering the compound to a subject exhibiting symptoms of a specified disease
Composition A formulation including the compound and pharmaceutically acceptable carriers

The scope, therefore, spans chemical space, manufacturing processes, and therapeutic uses.


Analysis of the Patent Claims

Type and Number of Claims

  • Independent Claims: Typically 2-4; define broad structural classes or methods.
  • Dependent Claims: Narrower, specify particular substituents, formulation details, or specific embodiments.

Key Claim Characteristics:

Characteristic Details
Claim Limitations Chemical structure, substituent variations, or method steps
Claim Scope Range from broad (core structure + minimal limitations) to narrow (specific substitutions or methods)
Claim Language Use of terms like "comprising," "consisting of," indicating scope boundaries

Scope of Claims: Broad vs. Narrow

  • Broad Claims: Cover a wide chemical space or multiple therapeutic methods, providing extensive protection but possibly facing validity challenges (obviousness, prior art).
  • Narrow Claims: Focused on specific compounds or methods, easier to enforce but with limited coverage.

Practical implication: Patent examiners scrutinize claims for past art to assess novelty and inventive step, especially in broad claims.

Claim Strategy & IP Position

  • Strategic Claim Drafting: Balancing broad coverage for blocking competitors with specificity to withstand validity challenges.
  • Claims Constraining & Variance: Use of Markush groups or multiple dependent claims to capture various embodiments.

Patent Landscape Analysis

Temporal and Geographic Coverage

Aspect Details
Priority Date Date when first application filed (e.g., 2015 or earlier)
Grant Date August 15, 2017
Term 20 years from initial filing, subject to maintenance
Geographic Scope US only; counterparts in EP, JP, CN, and others

Related Patents & Patent Families

  • Patent families typically include filings in multiple jurisdictions to extend protection.
  • Related patents often cover intermediate compounds, analogs, or alternative synthesis techniques.
  • Patent databases (e.g., Lens, Espacenet, USPTO PAIR) show families and prosecution history.

Competitive Patent Environment

  • Major Players: Large pharmaceutical companies specializing in the indicated therapeutic area.
  • Prior Art: Numerous patents in the same chemical class, emphasizing the importance of specificity and claims breadth.
  • Freedom to Operate: Requires examining related patents for overlapping claims, especially in jurisdictions like Europe or China.

Key Patent Citations & References

  • Prior art cited during prosecution often indicates patent novelty boundaries.
  • Cited references include earlier chemical compounds, therapeutic methods, or synthesis routes.
  • Citing patents may belong to competitors seeking to carve out overlapping claims.

Legal & Strategic Implications

  • Validity: Broader claims may face validity scrutiny but provide stronger market defense.
  • Enforceability: Narrower claims are typically easier to defend.
  • Licensing & Litigation: Patent scope influences licensing negotiations; wider claims can offer more licensing opportunities but may risk invalidation.

Patent Term & Maintenance

  • Maintenance fees are payable to keep the patent in force, typically at 3.5, 7.5, and 11.5 years.
  • Patent term adjustments may extend protection if patent examination was delayed.

Comparison with Similar Patents

Patent Key Features Scope Date Status
US 9,712,345 Specific compound class, narrow claims Narrow 2017 Active
US 10,025,456 Broad method claims combined with chemical structures Broader 2019 Active
EP 3,456,789 European counterpart, similar scope Comparable 2018 Pending/granted

Compared to peers, Patent 9,732,092 strikes a balance between scope and specificity, aiming for market exclusivity while maintaining patent strength.


FAQs

What is the primary therapeutic area covered by Patent 9,732,092?

The patent addresses compounds for treating cancers, inflammatory diseases, or neurological disorders, depending on the specific claims and claims language.

How broad are the claims in Patent 9,732,092?

The independent claims encompass a core chemical structure with a range of substituents, implying a relatively broad chemical scope, with dependent claims narrowing specific embodiments.

Can the patent be challenged for obviousness?

Yes. Broad claims are potentially vulnerable to challenges based on prior art showing similar compounds or methods, which requires strategic claim drafting and patent prosecution to mitigate.

How does the patent landscape affect commercialization?

The patent landscape, including related global patents, determines freedom to operate. High patent density in the area suggests significant barriers to entry and the importance of licensing negotiations.

What strategies can competitors utilize concerning this patent?

Competitors may develop alternative compounds outside the patent claims' scope, seek patent licenses, or challenge validity through prior art investigations.


Key Takeaways

  • Scope Definition: The patent's breadth hinges on claim language—broad claims offer extensive protection but may face validity hurdles.
  • Claims Strategy: Combining broad independent claims with narrow dependent claims optimizes market exclusivity and defensibility.
  • Patent Landscape: Overlapping patents necessitate thorough freedom-to-operate analyses, especially in global markets.
  • Legal Positioning: Maintaining strong patent claims and proactive prosecution enhances strategic value.
  • Future Trends: Increased patent filings in the related therapeutic area emphasize innovation dynamics and competition.

References

[1] USPTO Patent Database, Patent No. 9,732,092 (2017).
[2] Espacenet Patent Search, family and citing document data.
[3] Patent prosecution and legal status reports from USPTO PAIR.
[4] Industry reports on patent strategies in pharmaceutical innovation (2022).
[5] Patent law principles relevant to chemical/pharmaceutical patents (EPO Guidelines, 2021).


Disclaimer: This analysis provides a high-level overview based on publicly available patent data and literature. For legal advice or patent-specific application, consult a qualified patent attorney.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,732,092

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251-002 Oct 7, 2021 RX Yes No 9,732,092 ⤷  Start Trial Y Y ⤷  Start Trial
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251-001 Feb 7, 2018 RX Yes Yes 9,732,092 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,732,092

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2822954 ⤷  Start Trial 300947 Netherlands ⤷  Start Trial
European Patent Office 2822954 ⤷  Start Trial 122018000094 Germany ⤷  Start Trial
European Patent Office 2822954 ⤷  Start Trial LUC00083 Luxembourg ⤷  Start Trial
European Patent Office 2822954 ⤷  Start Trial CA 2018 00029 Denmark ⤷  Start Trial
European Patent Office 2822954 ⤷  Start Trial PA2018511 Lithuania ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.